Medpace, Inc. v. Darwin Select Insurance

13 F. Supp. 3d 839, 2014 U.S. Dist. LEXIS 47982, 2014 WL 1308515
CourtDistrict Court, S.D. Ohio
DecidedMarch 31, 2014
DocketCase No. 1:13-cv-784
StatusPublished
Cited by4 cases

This text of 13 F. Supp. 3d 839 (Medpace, Inc. v. Darwin Select Insurance) is published on Counsel Stack Legal Research, covering District Court, S.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Medpace, Inc. v. Darwin Select Insurance, 13 F. Supp. 3d 839, 2014 U.S. Dist. LEXIS 47982, 2014 WL 1308515 (S.D. Ohio 2014).

Opinion

ORDER: (1) DENYING DEFENDANT’S MOTION FOR JUDGMENT ON THE PLEADINGS (Doc. 16); AND (2) GRANTING PLAINTIFF’S MOTION FOR JUDGMENT ON THE PLEADINGS (Doc. 17)

TIMOTHY S. BLACK, District Judge.

This civil action is before the Court on the parties’ cross-motions for judgment on the pleadings (Doc. 16, 17) and responsive memoranda (Docs. 17,18).1

I. BACKGROUND FACTS

This ease arises out of Darwin’s refusal to defend and indemnify its insured, Med-pace, in the Underlying Lawsuit.2 In the Underlying Lawsuit, Defendant Biothera asserted a counterclaim against Medpace for conversion of certain data and information which Medpace generated and prepared (collectively, the “Trial Property”) for Biothera under a Master Services Agreement (“MSA”) between those two parties. (Doc. 3 at ¶ 4). Medpace tendered the counterclaim to Darwin for defense and indemnification pursuant to a Clinical Research Professional Liability Insurance Policy that Darwin had issued to Medpace (the “Policy”). (Id. at ¶ 3). Darwin refused to defend or indemnify Med-pace, claiming that the undefined term “research activities” in the Policy does not include a claim based on Medpace’s alleged wrongful refusal to turn over the Trial Property to Biothera. (Id. at ¶ 5).

A. The Policy

Darwin issued Clinical Research Professional Liability Insurance Policy No. 0307-1632 to Medpace for the policy period from December 3, 2011 to December 3, 2012. (Doc. 3 at ¶ 3). In relevant part, the Policy states:

I. INSURING AGREEMENTS A. CLINICAL RESEARCH PROFESSIONAL LIABILITY COVERAGE
The Insurer will pay on behalf of the Insured, and subject to the Limit of Liability set forth in ITEM 3(a) of the Declarations, Loss and Defense Expenses in excess of the Retention stated in ITEM 4(a) of the Declarations [843]*843which the Insured becomes legally obligated to pay as a result of a Claim for an act, error or omission by the Insured committed on or after the Retroactive Date in the Insured’s rendering of or failure to render Research-Related Services, provided always that such Claim is first made against the Insured and reported to the Insurer during the Policy Period or any applicable Extended Reporting Period.
III. DEFINITIONS
B. “Research-Related Services” means the following, when conducted by an Insured on behalf of the Named Insured: research activities, or consulting or advisory services performed for third parties for a fee or other consideration, in the fields of biomedical, behavioral, or veterinary research that is conducted in accordance with formal written protocols or procedures and is part of a controlled and regulated research study.

(Doc. 12-1 at §§ I.A and III.BB).

B. The Claim

The Underlying Lawsuit arises out of a MSA between Medpace and Biothera pursuant to which Medpace agreed to perform certain clinical trial and research activities for Biothera. (Doc. 16 at 3). On February 29, 2012, Biothera terminated the Master Services Agreement. (Id.) On March 2, 2012, Medpace initiated the Underlying Lawsuit, alleging breach of contract and unjust enrichment based on Biothera’s refusal to pay the money it owed Medpace under the MSA and the related Task Orders and Consulting Agreement. (Id.) Biothera filed a counterclaim for conversion, which alleged that: (1) Biothera owns the Trial Property generated by Medpace under the MSA; (2) Medpace had the Trial Property in its custody, control, and possession; and Medpace refused Bioth-era’s request to turn over the Trial Property. (Doc. 3 at ¶ 4).

Darwin argues that the Underlying Conversion Count has nothing to do with Med-pace’s rendering or failing to render professional services. Rather, it is about Medpace’s alleged wrongful conduct in attempting to force a former client into paying its fees, following the termination of its professional relationship with that client. Darwin claims that the Policy does not afford coverage for such a claim. Specifically, Darwin argues that the Underlying Conversion Count arises out of alleged conduct by Medpace committed after it had been removed from managing the Im-prime clinical drug trials, at a point in time when Medpace necessarily had ceased rendering or failing to render any “research activities ... performed for [Biothera] for a fee.” (Doc. 12-1 at § III.BB).

II. STANDARD OF REVIEW

The standard of review for a Rule 12(c) motion is the same as for a. motion under Rule 12(b)(6) for failure to state a claim upon which relief can be granted. Fritz v. Charter Twp. of Comstock, 592 F.3d 718, 722 (6th Cir.2010). “For purposes of a motion for judgment on the pleadings, all well-pleaded material allegations of the pleadings of the opposing party must be taken as true, and the motion may be granted only if the moving party is nevertheless clearly entitled to judgment.” Id. (citing JPMorgan Chase Bank v. Winget, 510 F.3d 577, 581 (6th Cir.2007)).

III. ANALYSIS

A. Interpretation of Insurance Policies

The interpretation of an insurance contract is a question of law for the [844]*844Court. Skinner v. Guarantee Trust Life Ins. Co., 813 F.Supp.2d 865, 868 (S.D.Ohio 2011). A court construing insurance policies “must enforce the contract as written and give the words their plain and ordinary meaning.” Cincinnati Indent. Co. v. Martin, 85 Ohio St.3d 604, 710 N.E.2d 677, 679 (1999). Where the provisions of an insurance policy are clear and unambiguous, courts may not rewrite the contract to expand coverage beyond that agreed to by the parties. Gomolka v. State Auto. Mut. Ins. Co., 70 Ohio St.2d 166, 436 N.E.2d 1347, 1348 (1982). Furthermore, any ambiguities in insurance policies are “interpreted against the insurer and in favor of the insured.” Skinner, 813 F.Supp.2d at 868.

The party seeking to recover under an insurance policy bears the burden of establishing that the particular loss falls within the policy’s insuring agreement. State Farm Fire & Cas. Co. v. Hiermer, 720 F.Supp. 1310, 1314 (S.D.Ohio 1988), aff'd 884 F.2d 580 (6th Cir.1989). It is well-settled law in Ohio that “where a term in an insurance contract is not defined by the policy, the term is to be given its ordinary meaning.” Morner v. Giuliano, 167 Ohio App.3d 785, 857 N.E.2d 602, 607 (2006). Similarly, “[ujnder black letter Ohio law, an undefined exclusionary term must be narrowly construed against the insurer.” Encore Receivable Mgmt., Inc. v. Ace Property & Cas. Ins. Co., No. 1:12cv297, 2013 WL 3354571, at *10, 2013 U.S. Dist. LEXIS 93513, at *38 (S.D.Ohio July 3, 2013).

B. Duty to Defend

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
13 F. Supp. 3d 839, 2014 U.S. Dist. LEXIS 47982, 2014 WL 1308515, Counsel Stack Legal Research, https://law.counselstack.com/opinion/medpace-inc-v-darwin-select-insurance-ohsd-2014.